The Patent Finder

Theramab LLC

Also on record
Records under this name other than patents Theramab LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Theramab LLC

PatentTitleStatus Expires Confidence
US 7,585,960Nucleic acids encoding superagonistic anti-CD28 antibodies
Term ended
Term ended May 11, 2026 · From the USPTO record
Term endedTerm ended May 11, 2026From the USPTO record
US 8,709,414Superagonistic anti-CD28 antibodies
Lapsed on the fee record
Ended Apr 29, 2026 · From the USPTO record
Lapsed on the fee recordEnded Apr 29, 2026From the USPTO record
US 8,034,585Superagonistic anti-CD28 antibodies
Lapsed on the fee record
Ended Oct 11, 2023 · From the USPTO record
Lapsed on the fee recordEnded Oct 11, 2023From the USPTO record
US 9,119,840Use of an active substance binding to CD28 for producing a pharmaceutical composition for activating and expanding T cells
Lapsed on the fee record
Ended Sep 1, 2023 · From the USPTO record
Lapsed on the fee recordEnded Sep 1, 2023From the USPTO record
US 7,939,638Superagonistic anti-CD28 antibodies
Lapsed on the fee record
Ended May 10, 2023 · From the USPTO record
Lapsed on the fee recordEnded May 10, 2023From the USPTO record
US 7,868,143Microparticle with cd28-specific monoclonal antibodies
Lapsed on the fee record
Ended Jan 11, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jan 11, 2023From the USPTO record
US 8,586,386Peptide or protein comprising a C′-D loop of the CD28 receptor family
Lapsed on the fee record
Ended Nov 19, 2021 · From the USPTO record
Lapsed on the fee recordEnded Nov 19, 2021From the USPTO record
US 8,389,016Use of a CD28 binding substance for making a pharmaceutical composition
Lapsed on the fee record
Ended Mar 5, 2021 · From the USPTO record
Lapsed on the fee recordEnded Mar 5, 2021From the USPTO record
US 8,334,102Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes
Formerly held
Term ended
Term ended May 28, 2018 · From the USPTO record
Term endedTerm ended May 28, 2018From the USPTO record
US 6,987,171Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes
Lapsed on the fee record
Ended Jan 17, 2018 · From the USPTO record
Lapsed on the fee recordEnded Jan 17, 2018From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited